Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adding <sup>161</sup>Dy-Mössbauer spectroscopy to a multitechnique investigation of magnetic transitions in a {Co<sup>III</sup><sub>3</sub>Dy<sup>III</sup><sub>3</sub>} Single-Molecule Toroic.

Nature communications·2026
Same author

Floating zone growth of high-purity MgO substrate single crystals.

Acta crystallographica Section B, Structural science, crystal engineering and materials·2026
Same author

Using a Radical Straitjacket to Enforce an Ultrashort Dy-Dy Distance and Thus Enhance Dipolar Interactions in a Dy<sup>III</sup><sub>2</sub> Dimer.

Inorganic chemistry·2025
Same author

Broadband frequency-doubling of a swept-source laser from 1550 nm to 775 nm using a fan-out crystal and application in 2kHz LiDAR ranging.

Optics express·2025
Same author

Sodium/hydrogen exchanger 8 affects sheet migration of human intestinal epithelial cells (HT29MTX) by influencing the actin cytoskeletal rearrangement.

American journal of physiology. Cell physiology·2025
Same author

Electronic structure of mononuclear and radical-bridged dinuclear cobalt(II) single-molecule magnets.

Nature communications·2025
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Temsirolimus.

Christian Stock1, Massimo Zaccagnini, Michael Schulze

  • 1Department of Urology, SLK-Kliniken Heilbronn GmbH, Medizinsche Klinik III, Germany. jens.rassweiler@slk-kliniken.de

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|January 15, 2010
PubMed
Summary
This summary is machine-generated.

Temsirolimus offers significant survival benefits for advanced renal cell carcinoma (RCC) patients compared to interferon-alpha. This mTOR inhibitor demonstrated improved overall survival and response rates with fewer adverse events.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Experiment Videos

Last Updated: Jun 17, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced renal cell carcinoma (RCC) presents a poor prognosis.
  • Current therapies like interferon-alpha (IFNalpha) have limitations.

Purpose of the Study:

  • To evaluate the efficacy and safety of temsirolimus in patients with advanced RCC.
  • To compare temsirolimus monotherapy against standard IFNalpha treatment.

Main Methods:

  • A large phase III clinical study was conducted.
  • Patients received a once-weekly intravenous (IV) infusion of temsirolimus (25 mg) or IFNalpha.
  • Overall survival, objective response rates, and adverse events were assessed.

Main Results:

  • Temsirolimus significantly improved median overall survival (10.9 vs. 7.3 months) compared to IFNalpha.
  • Objective response rates were higher with temsirolimus (8.6%) versus IFNalpha (4.8%).
  • Temsirolimus recipients experienced fewer grade 3 or 4 adverse events and fewer treatment withdrawals.

Conclusions:

  • Temsirolimus provides significant survival benefits for advanced RCC patients with poor prognosis.
  • Temsirolimus demonstrates a favorable safety profile compared to IFNalpha.
  • Temsirolimus represents an effective treatment option for advanced renal cell carcinoma.